clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT03959085 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P582 | end time | 2027-05-31 | |
P4135 | maximum age | 25 | |
P1050 | medical condition | leukemia | Q29496 |
P1132 | number of participants | 3698 | |
P4844 | research intervention | doxorubicin | Q18936 |
folic acid | Q127060 | ||
cytarabine | Q180983 | ||
2-aminopurine | Q209313 | ||
6-thioguanine | Q385347 | ||
(RS)-cyclophosphamide | Q408524 | ||
calcium oxalate | Q412399 | ||
methylprednisolone | Q417222 | ||
mercaptopurine | Q418529 | ||
asparaginase | Q421534 | ||
leucovorin calcium | Q27077063 | ||
prednisolone acetate | Q27108063 | ||
methylprednisolone hemisuccinate | Q27262132 | ||
prednisolone 21-phosphate | Q27266327 | ||
Caelyx | Q29004943 | ||
pegaspargase | Q7160547 | ||
prednisolone | Q11426176 | ||
P6153 | research site | Vanderbilt University | Q29052 |
Yale University | Q49112 | ||
West Virginia University | Q115376 | ||
University of Chicago | Q131252 | ||
University of Rochester | Q149990 | ||
University of North Carolina at Chapel Hill | Q192334 | ||
Johns Hopkins University | Q193727 | ||
University of Pittsburgh | Q235034 | ||
University of Minnesota | Q238101 | ||
Oregon Health & Science University | Q282097 | ||
Georgetown University | Q333886 | ||
Wake Forest University | Q392667 | ||
University of Miami | Q738258 | ||
Stony Brook University | Q969850 | ||
University of Illinois Urbana–Champaign | Q457281 | ||
Southern Illinois University Edwardsville | Q519349 | ||
McMaster University | Q632891 | ||
Cedars-Sinai Medical Center | Q1052562 | ||
Loma Linda University | Q1057447 | ||
Mayo Clinic | Q1130172 | ||
Dana–Farber Cancer Institute | Q1159198 | ||
East Carolina University | Q1277776 | ||
Indiana University – Purdue University Indianapolis | Q1433199 | ||
University of Colorado Denver | Q1468161 | ||
Mount Sinai Hospital | Q1476505 | ||
Memorial Sloan Kettering Cancer Center | Q1808012 | ||
New York Medical College | Q4115972 | ||
Cleveland Clinic | Q4117596 | ||
Children's Hospital of Philadelphia | Q4569202 | ||
Arkansas Children's Hospital | Q4791755 | ||
Arnold Palmer Hospital for Children | Q4795196 | ||
Baystate Medical Center | Q4874851 | ||
Children's Hospital of Orange County | Q5098129 | ||
Children's Hospital of The King's Daughters | Q5098131 | ||
Children's National Hospital | Q5098193 | ||
Cincinnati Children's Hospital Medical Center | Q5120231 | ||
Connecticut Children's Medical Center | Q5161492 | ||
Dayton Children's Hospital | Q5243510 | ||
Eastern Maine Medical Center | Q5330270 | ||
Augusta University | Q5547686 | ||
Loyola University Medical Center | Q6694611 | ||
Maimonides Medical Center | Q6735870 | ||
IWK Health Centre | Q14875689 | ||
Memorial Health University Medical Center | Q30253539 | ||
Cook Children's Medical Center | Q30254344 | ||
Duke University Medical Center | Q30279912 | ||
Atrium Health Navicent The Medical Center | Q6806287 | ||
Miami Children's Hospital | Q6827285 | ||
Miller Children's Hospital | Q6859100 | ||
Mission Health System | Q6878595 | ||
Morristown Medical Center | Q6914126 | ||
Newark Beth Israel Medical Center | Q7016630 | ||
Roswell Park Comprehensive Cancer Center | Q7370121 | ||
Santa Barbara Cottage Hospital | Q7419217 | ||
Tampa General Hospital | Q7681712 | ||
University Medical Center of Southern Nevada | Q7894830 | ||
University of Mississippi Medical Center | Q7895818 | ||
University of Nebraska Medical Center | Q7895888 | ||
University of Oklahoma Health Sciences Center | Q7896014 | ||
Washington University School of Medicine | Q7972509 | ||
Helen DeVos Children's Hospital | Q14716129 | ||
P580 | start time | 2019-11-23 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy |
Search more.